

Dear reviewers,

Thank you very much for your effort and time to read the paper and give your valuable comments. I tried to address all requested comments. All new inserted text is marked with yellow color. The HCC subsection was expanded, data of COVID-19 outcomes in autoimmune liver diseases were added, as well as data regarding severity and mortality in CLD patients. I hope that I managed to address all comments and that now the paper get new focus to distinguish this work from others.

1. Answers to the first reviewer

I read carefully the article titled Outcomes of COVID-19 among patients with liver disease and I found it a very we structured review article and to the point.

Thank you so much for your valuable and the great comments.

2. Answers to the second reviewer

In this review, Vujcic et al. have presented liver-related risk factors that could influence outcomes of COVID-19 infection and, to lesser extent, highlighted how COVID-19 may affect liver physiology from the recent literature. Although this piece of work is well written and includes major reports related to the topic, I'm afraid that the contents of this article are already reviewed elsewhere and thus represent redundancy (e.g. Marjot et al., 2021 PMID: 33692570; Dufour et al., 2022 PMID: 35701093; Du et al., 2022 PMID: 34428501; Ozkurt & Tanrıverdi, 2022 PMID: 35211548; McConnell et al., 2022 PMID: 34658172 and Aio, 2022 PMID: 35023684). In fact, some of these previous works provide more comprehensive details related to the topic. The authors should find a new focus regarding COVID-19 and liver diseases to distinguish or elevate this work from others.

Thank you very much for your valuable comments. In the revised manuscript it was added whole new section regarding severity and mortality of COVID-19 in CLD patients. Also, the HCC subsection was expanded and data of COVID-19 outcomes in autoimmune liver diseases were added. Thus I hope that the paper got new focus to distinguish this work from others.



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone:+1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

3. Answer to the third reviewer

The review is up-to-date, well-written, and contains relevant references without self-citation. However, as the review claims to be exhaustive, it is recommended to include data on COVID-19 outcomes in autoimmune/cholestatic liver disease (AIH, PBC, and PSC), expand the HCC subsection, and add data from large national studies (e.g., Mallet V. et al., 2021). The manuscript is recommended for publication after a minor revision.

Thank you very much for your valuable and nice comments. Data on COVID-19 outcomes in autoimmune/cholestatic liver disease (AIH, PBC, and PSC) have been added as new section.

HCC subsection was expanded.

Data from large national studies were added, including study of Mallet et al.

Best regards,
Isidora Vujcic